Develop novel targeted oncology therapies. Focus on unmet medical needs in cancer treatment. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
Executives buying with their own money is usually read as confidence in the company’s future.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
Clearly below the class average.
Clearly below the class average.
Clearly below the class average.
Clearly below the class average.
Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.
Business Quality: Profit power and business quality trail similar companies in the sector.
An investor who bought at the very peak is down 98% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Over the last 12 months, company executives reported 7 buys and 1 sell. Management buying with its own money is usually read as a good sign.
A loss of $24.8M against $0 in annual sales.
The stock sits at $0.92. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
This stock swings about 3.5 times as much as the market average. Big rallies — and big drops — can both happen fast.
On our five-subject report card, CTOR sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: CTOR is a high-risk stock — not yet profitable, and its future rides on its product catching on.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Analysts’ average target sits above today’s price, yet the valuation grade (23/100) says the stock isn’t cheap.
Not covered, because the filings we hold do not carry it: the revenue breakdown.